Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in PLWH

Alessandra Vergori
ORCID logo ,
Alessandro Cozzi-Lepri
* ORCID logo ,
Giulia Matusali
ORCID logo ,
Stefania Cicalini
,
Veronica Bordoni
,
Silvia Meschi
ORCID logo ,
Valentina Mazzotta
ORCID logo ,
Francesca Colavita
ORCID logo ,
Marisa Fusto
,
Eleonora Cimini
ORCID logo ,
Stefania Notari
,
Veronica D'Aquila
,
Simone Lanini
ORCID logo ,
Daniele Lapa
,
Roberta Gagliardini
,
Davide Mariotti
,
Giuseppina Giannico
,
Enrico Girardi
ORCID logo ,
Francesco Vaia
,
Chiara Agrati
,
Fabrizio Maggi
,
Andrea Antinori
ORCID logo
Version 1 : Received: 5 October 2023 / Approved: 6 October 2023 / Online: 6 October 2023 (05:08:35 CEST)

A peer-reviewed article of this Preprint also exists.

Vergori, A.; Cozzi-Lepri, A.; Matusali, G.; Cicalini, S.; Bordoni, V.; Meschi, S.; Mazzotta, V.; Colavita, F.; Fusto, M.; Cimini, E.; Notari, S.; D’Aquila, V.; Lanini, S.; Lapa, D.; Gagliardini, R.; Mariotti, D.; Giannico, G.; Girardi, E.; Vaia, F.; Agrati, C.; Maggi, F.; Antinori, A. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV. Vaccines 2023, 11, 1739. Vergori, A.; Cozzi-Lepri, A.; Matusali, G.; Cicalini, S.; Bordoni, V.; Meschi, S.; Mazzotta, V.; Colavita, F.; Fusto, M.; Cimini, E.; Notari, S.; D’Aquila, V.; Lanini, S.; Lapa, D.; Gagliardini, R.; Mariotti, D.; Giannico, G.; Girardi, E.; Vaia, F.; Agrati, C.; Maggi, F.; Antinori, A. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV. Vaccines 2023, 11, 1739.

Abstract

Background. Waning of neutralizing and cell-mediated immune response after the primary vac-cine cycle (PVC) and the first booster dose (BD) is of concern, especially for PLWH with a CD4 count ≤200 cells/ mm3.Methods.Neutralizing antibodies (nAbs) titers by microneutralization assay against WD614G /Omicron BA.1 and IFNγ production by ELISA assay were measured in samples of PLWH at 4 time points [2 and 4 months post-PVC (T1 and T2), 2 weeks and 5 months after the BD (T3 and T4)]. Participants were stratified by CD4 count after PVC (LCD4, <200/mm3; ICD4, 201-500/mm3 and HCD4, >500/mm3). Mixed models were used to compare mean responses over T1-T4 across CD4 groups. Results. 314 PLWH on ART (LCD4=56; ICD4=120; HCD4=138) were enrolled. At T2, levels of nAbs were significantly lower in LCD4 vs ICD4/HCD4 (p=0.04). BD was crucial for increasing nAbs titres above 1:40 at T3 and up to T4 for WD614G. A positive T cell response after PVC was observed in all groups, regardless of CD4 (p=0.31). Conclusions. Waning of nAbs after PVC was more important in LCD4 group. BD managed to re-establish higher levels of nAbs against WD614G which were retained for 5 months. The level of T-cellular response was significantly higher in HCD4 and ICD4 compared to the LCD4 group although it remained above detectable levels over the entire study period regardless of CD4 count. Keywords: HIV-1 infection; SARS-CoV-2 infection;

Keywords

HIV-1 infection; SARS-CoV-2 infection; Neutralizing antibodies; mRNA Vaccines; T-cell immunity; Immunity waning

Subject

Medicine and Pharmacology, Other

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.